CN106420901B - A kind of herbal mixture for treating fatty liver - Google Patents
A kind of herbal mixture for treating fatty liver Download PDFInfo
- Publication number
- CN106420901B CN106420901B CN201611113345.3A CN201611113345A CN106420901B CN 106420901 B CN106420901 B CN 106420901B CN 201611113345 A CN201611113345 A CN 201611113345A CN 106420901 B CN106420901 B CN 106420901B
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- herbal mixture
- treating fatty
- treatment
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 38
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 38
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 37
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000092668 Artemisia capillaris Species 0.000 claims abstract description 7
- 235000008658 Artemisia capillaris Nutrition 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims abstract description 6
- 239000006187 pill Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 235000019441 ethanol Nutrition 0.000 claims abstract description 4
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 229940100688 oral solution Drugs 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 241000700159 Rattus Species 0.000 abstract description 11
- 210000002966 serum Anatomy 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000002440 hepatic effect Effects 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 210000000952 spleen Anatomy 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 4
- 230000004089 microcirculation Effects 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 235000009200 high fat diet Nutrition 0.000 abstract description 3
- 230000006698 induction Effects 0.000 abstract description 3
- 239000007919 dispersible tablet Substances 0.000 abstract description 2
- 239000007901 soft capsule Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UYVVLXVBEQAATF-UHFFFAOYSA-N 4-(1,3,7,12-tetrahydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid Chemical compound OC1CC2CC(O)CC(O)C2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 UYVVLXVBEQAATF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000489492 Arisaema Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000005827 Arthrocnemum glaucum Nutrition 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 235000003042 Salicornia europaea Nutrition 0.000 description 1
- 240000002625 Salsola soda Species 0.000 description 1
- 241001339782 Scapharca broughtonii Species 0.000 description 1
- 240000000260 Typha latifolia Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 208000026475 palpebral edema Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of herbal mixture for treating fatty liver, is related to herbal mixture.The raw material composition of the herbal mixture of the treatment fatty liver in mass ratio are as follows: spina gleditsiae 0.5~1, raw Rhizoma Atractylodis Macrocephalae 0.5~1, Artemisia capillaris 1~2.The herbal mixture of the treatment fatty liver can be used suitable for preparation for oral use, can be selected from one of tablet, capsule, soft capsule, granule, dripping pill, dispersible tablet, oral disnitegration tablet, pill, oral solution etc..The herbal mixture of the treatment fatty liver is taken after can decocting, and takes after can also being extracted with water or ethyl alcohol.Have the function of clearing heat and expelling damp, activating microcirculation and removing stasis medicinal, strengthening the spleen and replenishing qi.The Rats with Fatty Liver hepatic tissue TG content of high fat diet induction can be reduced, Serum ALT, the active raising of AST are inhibited, has the function for the treatment of fatty liver, can be used for preparing the drug for the treatment of fatty liver.
Description
Technical field
The present invention relates to herbal mixtures, more particularly, to a kind of herbal mixture for treating fatty liver.
Background technique
In recent years, with diet structure, living-pattern preservation, the disease incidence of China's fatty liver constantly increases and the low age that becomes
Change, occur as chronic liver diseases such as liver fibrosis, cirrhosis, liver cancer, development an important factor for, it is most likely that the as China
One big hepatopathy.Currently, modern medicine is mostly to move, lose weight etc. as essential therapeutic arsenals, chemicals need to take for a long time, even
There is adverse reactions, the clinical applications such as liver renal toxicity to be restricted.And Chinese medicine compound prescription has the pharmacology effect of multipath, too many levels
It answers, is that the advantage of its organic conception embodies, has become a kind of Critical policies of lipotropism research.Therefore, reinforce this disease
Research be reduce and prevent chronic liver disease be in progress important measures, have important social effect and economic significance.
Chinese patent CN102293969A discloses a kind of Chinese medicine for treating fatty liver.Its effective component is by following weight
The bulk pharmaceutical chemicals of part are made: Radix Paeoniae Alba 5~8, the shell of seaear 8~12, Prunella vulgaris 6~10, blood clam 4~6, mother-of-pearl 4~6, spina gleditsiae 5
~8, hawthorn 10~15, Poria cocos 4~6, arisaema cum bile 4~6, cortex moutan 6~10, Radix Salviae Miltiorrhizae 6~10, trigone 5~8, the fleece-flower root 8~
12, peach kernel 6~10.
Chinese patent CN104815299A discloses a kind of for treating the Chinese medicine of fatty liver, it is by following weight proportion
Raw medicinal material is prepared: 30 parts of Artemisia capillaris breaks by a fall and strangles 30 parts, 6 parts of glasswort, 6 parts of Fructus meliae toosendan, 6 parts of corydalis tuber, excrementum pteropi 10
Part, 15 parts of indigo naturalis, 15 parts of sugarcane worm, 6 parts of Radix Curcumae.
Chinese patent CN105381334A discloses a kind of compound Chinese medicinal preparation for treating fatty liver, it is with radix pseudostellariae, the heart of a lotus seed
The seed of jog's tears, Poria cocos, rhizoma atractylodis macrocephalae, Chinese yam, astragalus root, dried orange peel, Radix Paeoniae Alba, lotus leaf, RADIX ANGELICAE SINEINSIS, endothelium corneum gigeriae galli, Artemisia capillaris are raw material, by system
For at medicament.
Chinese patent CN105663497A disclose it is a kind of treat fatty liver Chinese medicinal formulae, the prescription Ingredients Weight is such as
Under: 10~13 grams of Radix Salviae Miltiorrhizae, 22~24 grams of oriental wormwood, 7~10 grams of rhizoma alismatis, 16~18 grams of radish seed, 20~25 grams of Artemisia capillaris, semen brassicae
20~30 grams, 25~30 grams of PORIA ALBA, 10~15 grams of hawthorn, 14~17 grams of Radix Notoginseng, 7~9 grams of the fleece-flower root, 6~8 grams of cattail pollen, reed
4~8 grams of luxuriant growth, 3~7 grams of leech, 8~10 grams of dried orange peel.
Summary of the invention
The object of the present invention is to provide a kind of herbal mixtures for treating fatty liver.
The raw material composition of the herbal mixture of the treatment fatty liver in mass ratio are as follows: spina gleditsiae 0.5~1, raw Rhizoma Atractylodis Macrocephalae 0.5~
1, Artemisia capillaris 1~2.
The herbal mixture of the treatment fatty liver can be used suitable for preparation for oral use, can be selected from tablet, capsule, flexible glue
One of wafer, granule, dripping pill, dispersible tablet, oral disnitegration tablet, pill, oral solution etc..
The herbal mixture of the treatment fatty liver can be mixed with carrier common in pharmacy or auxiliary material, be made various oral
Dosage form；The carrier can be selected from excipient, filler, diluent, lubricant, wetting agent, disintegrating agent, surfactant, preservative,
At least one of sweetener, aromatic etc.；Specifically, the carrier can be selected from starch, dextrin, lactose, microcrystalline cellulose, hydroxyl
In third methylcellulose, polyethylene glycol, magnesium stearate, superfine silica gel powder, glucose, mannitol, xylitol, glycine etc. at least
It is a kind of.
The herbal mixture of the treatment fatty liver is taken after can decocting, and takes after can also being extracted with water or ethyl alcohol.
The present invention has the function of clearing heat and expelling damp, activating microcirculation and removing stasis medicinal, strengthening the spleen and replenishing qi.Pharmacological research shows that the present invention can reduce
The Rats with Fatty Liver hepatic tissue TG content of high fat diet induction, inhibits Serum ALT, the active raising of AST, has treatment fatty liver
Effect, can be used for preparing treatment fatty liver drug.
The present invention is extracted by 0~75% ethyl alcohol and is separated, be made certain using spina gleditsiae, raw Rhizoma Atractylodis Macrocephalae, Artemisia capillaris as raw material
Dosage form.Above-mentioned three medicine shares, clearing heat and expelling damp, activating microcirculation and removing stasis medicinal, strengthening the spleen and replenishing qi, for fatty liver belong to the hot stasis of blood mutually tie, the insufficiency of the spleen with overabundance of dampness
Person.Pharmacodynamic study shows: Chinese medicine composition can reduce the Rats with Fatty Liver hepatic tissue TG content of high fat diet induction, inhibit blood
The active raising of clear ALT, AST has the function for the treatment of fatty liver, can be used for preparing the drug for the treatment of fatty liver.The combination
Medically acceptable oral preparation, such as tablet, capsule (soft capsule or hard capsule), granule agent can be made in object
Type proves that the present invention has the function of clearing heat and expelling damp, activating microcirculation and removing stasis medicinal, strengthening the spleen and replenishing qi from pharmacodynamic study, is to treat fatty liver
Effective special medicine.
Detailed description of the invention
Fig. 1 is influence (HE dyeing × 200) of the present invention to SD liver tissues of rats pathology.In Fig. 1, a is normal group, b
For model group, c is of the present invention group.
Specific embodiment
In order to the present invention be further described in detail, provide specific embodiment, but only conduct illustrate the present invention,
The range being not intended to be limiting of the invention.It is specific as follows:
1 material
1.1 experimental animal SD male rats, 30, cleaning grade, 200g or so, by Chinese Academy of Sciences Shanghai experimental animal
Center provides.
1.2 drugs and reagent TG kit, ALT kit, AST kit are purchased from Nanjing and build up bio-engineering research
Institute.
1.3 high lipid food high lipid foods composition: 83.25% basal feed, 10% lard, 1.5% cholesterol, 0.2% take off
Oxycholic acid sodium, 5% sugar, 0.05% propylthiouracil (PTU), are provided by Suzhou Shuan Shi animal feed Co., Ltd.
2 methods
SD rat by table of random number, is divided into normal group, model group from the modeling by 2.1 modelings and grouping medication
With the present invention group it is each 6, model group, of the present invention group give high lipid food modeling, normal group is given chow diet.From 7th week, this
Invention group by 100ml/Kg mouse weight (containing crude drug amount be 0.1g/100ml) gavage medical fluid 6 weeks, normal group, model group give corresponding amount
Drinking water stomach-filling.
2.2 detection project
2.2.1 hepatic tissue TG assay
2.2.2 Serum ALT, AST Activity determination
2.2.3 hepatic tissue pathology HE is dyed
3 results
Influence of 3.1 present invention to SD liver tissues of rats TG content
Compared with normal group, model group TG content significantly increases (P < 0.01), and of the present invention group of hepatic tissue TG content is compared with model group
It significantly reduces (P < 0.01) (being shown in Table 1).
3.2 present invention are on the active influence of SD rat blood serum ALT, AST
Compared with normal group, model group Serum ALT, AST activity significantly increase (P < 0.01), of the present invention group of Serum ALT,
AST activity then compared with model group significantly reduce (P < 0.01) (normal group, model group, of the present invention group to SD liver tissues of rats TG content
And the active influence of Serum ALT, AST is compared and is shown in Table 1)
Table 1
Note:**Normal group of P < 0.01, vs；ΔΔP < 0.01, vs model group.
Influence of 3.3 present invention to SD liver tissues of rats HE dyeing
Normal group SD rat hepatocytes rope arrangement is normal, and liver cell form is normal, and core is round, big, placed in the middle, without fat drips in endochylema
It accumulates, no inflammation cellular infiltration in leaflet.Compared with normal group, for model group liver there are obvious steatosis, the liver of denaturation is thin
Palpebral edema is rounded greatly, occurs significant quantities of fat vacuole in endochylema, and part cell visible cell core is pressed against side, and the visible point being dispersed in
Shape necrosis region and inflammatory cell infiltration.Of the present invention group of hepatic steatosis degree and cellular swelling are substantially reduced, fat drips number intracellular
Amount is reduced, and volume becomes smaller, and inflammatory cell infiltration and necrosis region reduce (see Fig. 1).
These results suggest that herbal mixture has the function for the treatment of fatty liver.
Claims (8)
1. a kind of herbal mixture for treating fatty liver, it is characterised in that its in mass ratio raw material composition are as follows: spina gleditsiae 0.5~1,
Raw Rhizoma Atractylodis Macrocephalae 0.5~1, Artemisia capillaris 1~2.
2. a kind of herbal mixture for treating fatty liver as described in claim 1, it is characterised in that using suitable for preparation for oral use.
3. a kind of herbal mixture for treating fatty liver as claimed in claim 2, it is characterised in that described to be suitable for preparation for oral use
Selected from one of tablet, capsule, granule, pill, oral solution.
4. a kind of herbal mixture for treating fatty liver as described in claim 1, it is characterised in that with carrier common in pharmacy
Or auxiliary material mixing, various peroral dosage forms are made.
5. a kind of herbal mixture for treating fatty liver as claimed in claim 4, it is characterised in that the carrier is selected from excipient, fills out
At least one of material, diluent, lubricant, wetting agent, disintegrating agent, surfactant, preservative, sweetener, aromatic.
6. a kind of herbal mixture for treating fatty liver as described in claim 4 or 5, it is characterised in that the carrier be selected from starch,
Dextrin, lactose, microcrystalline cellulose, hypromellose, polyethylene glycol, magnesium stearate, superfine silica gel powder, glucose, mannitol,
At least one of xylitol, glycine.
7. a kind of herbal mixture for treating fatty liver as described in claim 1, it is characterised in that taken after decoction.
8. a kind of herbal mixture for treating fatty liver as described in claim 1, it is characterised in that taken after being extracted with water or ethyl alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611113345.3A CN106420901B (en) | 2016-12-07 | 2016-12-07 | A kind of herbal mixture for treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611113345.3A CN106420901B (en) | 2016-12-07 | 2016-12-07 | A kind of herbal mixture for treating fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106420901A CN106420901A (en) | 2017-02-22 |
| CN106420901B true CN106420901B (en) | 2019-08-13 |
Family
ID=58216173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611113345.3A Active CN106420901B (en) | 2016-12-07 | 2016-12-07 | A kind of herbal mixture for treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420901B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199714A (en) * | 2006-12-11 | 2008-06-18 | 孙蓉 | Chinese medicine compound for treating alcohol fatty liver and preparing method thereof |
| CN101797281A (en) * | 2010-04-15 | 2010-08-11 | 刘恒禄 | Medicinal granules for toxin elimination and blood fat reduction |
| CN105796676A (en) * | 2016-05-19 | 2016-07-27 | 葛文农 | Pills for effectively treating fatty liver |
-
2016
- 2016-12-07 CN CN201611113345.3A patent/CN106420901B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199714A (en) * | 2006-12-11 | 2008-06-18 | 孙蓉 | Chinese medicine compound for treating alcohol fatty liver and preparing method thereof |
| CN101797281A (en) * | 2010-04-15 | 2010-08-11 | 刘恒禄 | Medicinal granules for toxin elimination and blood fat reduction |
| CN105796676A (en) * | 2016-05-19 | 2016-07-27 | 葛文农 | Pills for effectively treating fatty liver |
Non-Patent Citations (4)
| Title |
|---|
| 皂术茵陈方治疗非酒精性脂肪性肝炎40例临床研究;陈少东等;《中医药通报》;20150228;第14卷(第1期);第46-48页 |
| 皂术茵陈方治疗非酒精性脂肪性肝炎的临床疗效及对游离脂肪酸和TNF-α的影响;唐金模等;《中国中西医结合杂志》;20160531;第36卷(第5期);第545页右栏第4节 |
| 茵陈蒿汤防治大鼠非酒精性脂肪性肝炎的实验研究;梁惠卿等;《光明中医》;20090228;第24卷(第2期);第212-214页 |
| 茵陈醇提物抗游离脂肪酸对体外培养HepG2细胞脂毒性的作用及机制研究;陈少东等;《中国中药杂志》;20090930;第34卷(第18期);第2373-2377页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106420901A (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102106957B (en) | Chinese medicinal composition for treating hyperlipidemia | |
| CN102139084B (en) | Chinese medicinal composition for treating fatty liver and preparation method and application thereof | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN103933220B (en) | Medicine for treating climacteric syndrome | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN102813857A (en) | Chinese herbal Siyu blood-tonifying and kidney-nourishing preparation | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN103285319B (en) | Chinese medicine composition for Polycystic Ovary Syndrome in Adolescence | |
| CN105853678A (en) | Traditional Chinese medicinal composition for treating membranous nephropathy and method for preparing traditional Chinese medicinal composition for treating membranous nephropathy | |
| CN102429977B (en) | Medicine for treating diabetes | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN106420901B (en) | A kind of herbal mixture for treating fatty liver | |
| CN103877323B (en) | Medicinal composition for treating non-alcoholic fatty liver disease | |
| CN104958615B (en) | A kind of Chinese medicine composition of prevention and treatment II diabetes and preparation method thereof | |
| CN106535912A (en) | Pharmaceutical composition for controlling blood lipids and body weight, and use thereof | |
| CN108403919B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
| CN100551396C (en) | A kind of Chinese patent medicine for the treatment of fatty liver and preparation method thereof | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
| CN103041233A (en) | Pharmaceutical composition for treating infantile diarrhea and preparation method thereof | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN103041288B (en) | A kind of Chinese medicine composition and preparation technology treating diabetic fatty liver | |
| CN101375962B (en) | Formulation for activating blood and freeing collateral vessels and preparation method thereof | |
| CN104547910A (en) | Medicine application of Huang'e capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |